NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
Clinical Trials
105 trialsNCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT02481154 2026-02-17
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Servier
Phase 1 Completed
NCT03343197 2026-02-17
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Servier
Phase 1 Completed
NCT04773782 2026-01-13
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation
Phase 1/2 Completed
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT04998864 2025-12-23
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients
InSightec
Completed
NCT03050736 2025-09-04
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT01478178 2025-08-29
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Kintara Therapeutics, Inc.
Phase 1/2 Completed
NCT02717962 2025-08-29
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT04388475 2025-08-12
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Oblato, Inc.
Phase 2 Completed
NCT05383872 2025-07-28
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors
InSightec
Phase NA Completed
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT05362409 2025-06-19
Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma
Alpheus Medical, Inc.
Phase 1 Completed
NCT04734444 2025-06-17
SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue
SonoClear AS
Phase NA Completed
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT00526812 2025-05-28
A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
Biogen
Phase 1 Completed
NCT01682187 2024-11-07
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Eli Lilly and Company
Phase 1 Completed
NCT03234595 2024-09-19
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
Everfront Biotech Co., Ltd.
Phase 1/2 Completed
NCT05305378 2024-08-07
Intraoperative Laser Speckle Contrast Imaging of Cerebral Blood Flow
Dynamic Light
Completed
NCT02490800 2024-06-26
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
Basilea Pharmaceutica
Phase 1/2 Completed
NCT03257631 2024-04-16
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Celgene
Phase 2 Completed
NCT03043391 2024-04-08
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
Phase 1 Completed
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT03551249 2024-03-05
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
InSightec
Phase NA Completed
NCT00704288 2024-02-05
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Exelixis
Phase 2 Completed
NCT02571036 2023-12-13
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT02684058 2023-12-13
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
Phase 2 Completed
NCT02315534 2023-11-15
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04446416 2023-09-06
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Phase NA Completed
NCT03245151 2023-08-30
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
Phase 1/2 Completed
NCT00751270 2023-08-25
BrTK01
Candel Therapeutics, Inc.
Phase 1 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT01290692 2023-07-03
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase 2 Completed
NCT01081223 2023-06-01
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVAX Biomedical
Phase 1/2 Completed
NCT04089449 2023-04-05
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
Prelude Therapeutics
Phase 1 Completed
NCT01792310 2023-02-21
A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours
Laminar Pharmaceuticals
Phase 1/2 Completed
NCT02858895 2022-10-24
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Medicenna Therapeutics, Inc.
Phase 2 Completed
NCT01137604 2022-09-29
A Study in Subjects With Recurrent Malignant Glioma
Eisai Inc.
Phase 2 Completed
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT02750891 2022-04-12
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
Sumitomo Pharma Co., Ltd.
Phase 1/2 Completed
NCT02526017 2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT05100173 2021-11-22
Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
Genetron Health
Completed
NCT05100602 2021-11-22
Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
Genetron Health
Completed
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT02903069 2021-04-19
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Celgene
Phase 1 Completed
NCT02273739 2021-02-23
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
Phase 1/2 Completed
NCT00031083 2020-11-17
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Biogen
Phase 1 Completed